Shandong Cancer Hospital achieves milestone with advanced radiotherapy technology.
Accuray Incorporated announced that Shandong Cancer Hospital and Institute successfully treated 100 patients using the Tomo® C Radiation Treatment Delivery System, developed through the CNNC-Accuray joint venture. This milestone highlights the system’s role in expanding clinical capabilities and increasing access to personalised cancer treatment in China.
Meeting China’s Growing Cancer Care Needs
- Rising cancer cases: New diagnoses in China are projected to grow 47% by 2045, reaching 7.1 million annually, compared to 4.8 million in 2022.
- Enhanced capacity: The Tomo C System allows treatment of 95 fractions per day, accelerating care delivery.
Suzanne Winter, President and CEO of Accuray, remarked:
“The system expands our product portfolio and reinforces our commitment to delivering fast, effective, and personalised cancer care.”
Advanced Technology for Precision Radiotherapy
The Tomo C System, based on the helical TomoTherapy® platform, integrates advanced imaging, planning, and delivery to ensure ultra-precise treatments.
Prof. Yu, President of Shandong Cancer Hospital, said:
“This achievement sets a new benchmark for cancer care, enabling us to treat a wide range of cases efficiently while supporting the ‘Healthy China Initiative.'”
Impactful Innovation
With this milestone, Accuray and Shandong Cancer Hospital demonstrate the transformative potential of advanced radiotherapy in meeting the needs of China’s underserved cancer patients.
Follow MEDWIRE.AI for more insights on breakthroughs in oncology technology.
